Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Finlabo SIM Spa
$10.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fresenius Medical Care AG & Co KGaA confirms its FY 2014 guidance in line with analysts estimates


Tuesday, 6 May 2014 01:38am EDT 

Fresenius Medical Care AG & Co KGaA:Expects revenue to be at around $15.2 billion in 2014, translating into a growth rate of around 4 pct, I/B/E/S Estimates revenue of $15.281 billion for 2014.Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014, I/B/E/S Estimates for 2014 net income of $1.120 billion.Expects to spend around $900 million on capital expenditures in 2014, I/B/E/S Estimates capex of $874.62 million for 2014.